Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 3Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Completed 7Recruiting 2Active not recruiting 2Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 4NIH 3

Study Type

Interventional 7

Sponsor

Cancer Type

CNS 5Sarcoma 2

Conditions

Neuroblastoma 4Ganglioneuroblastoma 2Osteosarcoma 1Neoplasm, Residual 1Leiomyosarcoma 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Completed × dinutuximab × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT02308527 2026-05-12

BEACON

University of Birmingham

Phase 2 Completed
225 enrolled
CNS

Neuroblastoma

NCT01857934 2026-04-16

Therapy for Children With Advanced Stage Neuroblastoma

St. Jude Children's Research Hospital

Phase 2 Completed
153 enrolled 12 charts
CNS

Neuroblastoma

NCT05080790 2025-08-17

DiTuSarc

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed
7 enrolled
Sarcoma

Leiomyosarcoma

NCT02169609 2024-04-22

Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

Fundació Sant Joan de Déu

Phase 2 Completed
24 enrolled
CNS

Neuroblastoma, Neoplasm, Residual

NCT02484443 2023-10-26

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 15 charts
Sarcoma

Osteosarcoma

NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 12 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡